TOKYO (AP) -- Japanese drugmaker Eisai Co. said Monday it will buy U.S. biopharmaceutical company MGI Pharma Inc. for $3.9 billion in cash in a move aimed at boosting its cancer drug business and sustain sales growth.
东京—日本制药公司Eisai在本周一宣布，为了扩展其在抗癌药物方面的业务并保持销售的不断增长，它将以39亿现金收购美国的生物制药公司MGI Pharma。
MGI Pharma's board unanimously approved the deal after examining a number of strategic options. Eisai expects to complete the deal in the first quarter of 2008.
MGI Pharma的董事会在对一些战略选择进行权衡后一致批准了这项交易。Eisai希望能在2008年的第一季度内完成收购。
The Bloomington, Minn.-based drugmaker spoke with ''many of the leading companies in the phamaceutical and biotechnology industry'' before agreeing to the Eisai buyout, MGI Chief Executive Lonnie Moulder said in a statement.
MGI的CEO Lonnie Moulder先生在一份声明中承认，这家位于Bloomington的制药企业在接受Eisai的收购提议之前曾和许多在制药和生物技术领域中处于领导地位的企业洽谈过。
''Eisai has enormous respect for MGI Pharma's products, pipeline and people,'' the statement quoted Eisai President and CEO Haruo Naito as saying.
Eisai的主席兼CEO Haruo Naito先生在一份声明中说：“Eisai对MGI Pharma的产品、生产线和人员都怀有巨大的敬意。”
''We expect this transaction to allow Eisai to significantly strengthen its oncology business and increase the likelihood of achieving our current strategic plan targets and our future revenue and earnings growth,'' he said.
他说：“我们希望这次收购能够使Eisai的抗癌药业务得到加强，使我们实现目前战略计划和未来收入增长的可能性大大增加。”
Eisai agreed to pay $41.00 in cash for each of MGI Pharma's shares, the companies said. That is a 22.6 percent premium over Friday's close and a 38.7 percent premium over MGI Pharma's closing price of $29.55 on Nov. 28, the last business day prior to its announcement that it was exploring strategic alternatives, the statement said.
声明中说：Eisai同意以每股41美元的价格收购MGI Pharma的股票，这个价格与周五股票的收盘价相比有22.6%的溢价，与11月28日（公告存在战略性改变的日期）的收盘价（29.55美元）相比有38.7%的溢价
MGI Pharma shares rose $6.55, or 19.6 percent, to close at $40 Monday after rising to a 52-week high of $40.23 earlier in the session.
本周一（声明公布后）MGI Pharma的股票价格上升了6.55美元（19.6%），达到40美元，在此之前股价曾经涨到过40.23美元（这个价格是52个星期里的最高价）
Faced with the expiration of its U.S. patent on its best-selling Aricept Alzheimer's disease treatment in 2010, Eisai has been keen to expand its product lineup and research in cancer treatment.
由于Eisai的最畅销药品Aricept（治疗老年痴呆症）在美国的专利保护将于2010年到期，所以它已经
MGI Pharma makes Aloxi, an injection for cancer patients to help prevent post-chemotherapy nausea and vomiting. It also sells injectable Dacogen for the treatment of bone marrow disease myelodysplastic syndrome, the Gliadel Wafer for brain cancer, and Hexalen, a chemotherapy treatment for ovarian cancer.
MGI Pharma生产的Aloxi是一种注射剂，用于治疗癌症病人化疗后的呕吐和恶心症状；它还销售Dacogen，用于治疗脊髓发育不良综合征；Gliadel Wafer用于治疗脑癌以及Hexalen（一种用于治疗卵巢癌的一种化疗药物）
The company reported 2006 sales of $342.8 million.
这家公司2006年的销售额是3.428亿美元。
Eisai's purchase of MGI would be its third major acquisition in the oncology area in recent years. Eisai bought Morphotek Inc. of the U.S. in April and four cancer drugs from Ligand Pharmaceuticals Inc. last year.
Eisai收购MGI是它近几年在抗肿瘤药物领域里的第三次大的收购。它今年4月份收购了美国的Morphotek Inc公司以及去年从Ligand Pharmaceuticals Inc购买了4种抗癌药物。
Drugmakers have been on the hunt for acquisitions, particularly companies with strong antibody and biopharmaceutical technologies, as they try to cushion the impact of expiring patents in the coming years.
大型制药一直在寻觅合适的收购目标，特别是那些有较强抗癌和生物技术的公司，已抵消未来几年因专利到期造成的不良影响。
Other deals this year include Celgene Corp.'s $2.9 billion bid for Pharmion last month and AstraZeneca PLC's $15.6 billion purchase of MedImmune this summer.
The deal was announced after the close of trade on the Tokyo Stock Exchange, where Eisai shares rose 2.1 percent to finish Monday at 4,840 yen ($43.35).
今年其他的收购案包括上个月Celgene Corp.以29亿美元收购Pharmion，今年夏天阿斯利康以156亿美元收购MedImmune。这则收购的消息是在东京股市结束交易后宣布的，周一Eisai的股价上涨2.1%4840日圆（43.35美元）
The company reported 2006 sales of $342.8 million.
这家公司2006年的销售额是342.8万美元。这句话翻译有问题吧，应该是这家公司2006年的销售额是3亿4千2百8十万美元吧
,已经改正
东京—日本制药公司Eisai在本周一宣布，为了扩展其在抗癌药物方面的业务并保持销售的不断增长，它将以39亿现金收购美国的生物制药公司MGI Pharma。
MGI Pharma's board unanimously approved the deal after examining a number of strategic options. Eisai expects to complete the deal in the first quarter of 2008.
MGI Pharma的董事会在对一些战略选择进行权衡后一致批准了这项交易。Eisai希望能在2008年的第一季度内完成收购。
The Bloomington, Minn.-based drugmaker spoke with ''many of the leading companies in the phamaceutical and biotechnology industry'' before agreeing to the Eisai buyout, MGI Chief Executive Lonnie Moulder said in a statement.
MGI的CEO Lonnie Moulder先生在一份声明中承认，这家位于Bloomington的制药企业在接受Eisai的收购提议之前曾和许多在制药和生物技术领域中处于领导地位的企业洽谈过。
''Eisai has enormous respect for MGI Pharma's products, pipeline and people,'' the statement quoted Eisai President and CEO Haruo Naito as saying.
Eisai的主席兼CEO Haruo Naito先生在一份声明中说：“Eisai对MGI Pharma的产品、生产线和人员都怀有巨大的敬意。”
''We expect this transaction to allow Eisai to significantly strengthen its oncology business and increase the likelihood of achieving our current strategic plan targets and our future revenue and earnings growth,'' he said.
他说：“我们希望这次收购能够使Eisai的抗癌药业务得到加强，使我们实现目前战略计划和未来收入增长的可能性大大增加。”
Eisai agreed to pay $41.00 in cash for each of MGI Pharma's shares, the companies said. That is a 22.6 percent premium over Friday's close and a 38.7 percent premium over MGI Pharma's closing price of $29.55 on Nov. 28, the last business day prior to its announcement that it was exploring strategic alternatives, the statement said.
声明中说：Eisai同意以每股41美元的价格收购MGI Pharma的股票，这个价格与周五股票的收盘价相比有22.6%的溢价，与11月28日（公告存在战略性改变的日期）的收盘价（29.55美元）相比有38.7%的溢价
MGI Pharma shares rose $6.55, or 19.6 percent, to close at $40 Monday after rising to a 52-week high of $40.23 earlier in the session.
本周一（声明公布后）MGI Pharma的股票价格上升了6.55美元（19.6%），达到40美元，在此之前股价曾经涨到过40.23美元（这个价格是52个星期里的最高价）
Faced with the expiration of its U.S. patent on its best-selling Aricept Alzheimer's disease treatment in 2010, Eisai has been keen to expand its product lineup and research in cancer treatment.
由于Eisai的最畅销药品Aricept（治疗老年痴呆症）在美国的专利保护将于2010年到期，所以它已经
MGI Pharma makes Aloxi, an injection for cancer patients to help prevent post-chemotherapy nausea and vomiting. It also sells injectable Dacogen for the treatment of bone marrow disease myelodysplastic syndrome, the Gliadel Wafer for brain cancer, and Hexalen, a chemotherapy treatment for ovarian cancer.
MGI Pharma生产的Aloxi是一种注射剂，用于治疗癌症病人化疗后的呕吐和恶心症状；它还销售Dacogen，用于治疗脊髓发育不良综合征；Gliadel Wafer用于治疗脑癌以及Hexalen（一种用于治疗卵巢癌的一种化疗药物）
The company reported 2006 sales of $342.8 million.
这家公司2006年的销售额是3.428亿美元。
Eisai's purchase of MGI would be its third major acquisition in the oncology area in recent years. Eisai bought Morphotek Inc. of the U.S. in April and four cancer drugs from Ligand Pharmaceuticals Inc. last year.
Eisai收购MGI是它近几年在抗肿瘤药物领域里的第三次大的收购。它今年4月份收购了美国的Morphotek Inc公司以及去年从Ligand Pharmaceuticals Inc购买了4种抗癌药物。
Drugmakers have been on the hunt for acquisitions, particularly companies with strong antibody and biopharmaceutical technologies, as they try to cushion the impact of expiring patents in the coming years.
大型制药一直在寻觅合适的收购目标，特别是那些有较强抗癌和生物技术的公司，已抵消未来几年因专利到期造成的不良影响。
Other deals this year include Celgene Corp.'s $2.9 billion bid for Pharmion last month and AstraZeneca PLC's $15.6 billion purchase of MedImmune this summer.
The deal was announced after the close of trade on the Tokyo Stock Exchange, where Eisai shares rose 2.1 percent to finish Monday at 4,840 yen ($43.35).
今年其他的收购案包括上个月Celgene Corp.以29亿美元收购Pharmion，今年夏天阿斯利康以156亿美元收购MedImmune。这则收购的消息是在东京股市结束交易后宣布的，周一Eisai的股价上涨2.1%4840日圆（43.35美元）
The company reported 2006 sales of $342.8 million.
这家公司2006年的销售额是342.8万美元。这句话翻译有问题吧，应该是这家公司2006年的销售额是3亿4千2百8十万美元吧
,已经改正